ABCAM up as it completes acquisitions

0 mins. to read
ABCAM up as it completes acquisitions
Master Investor Magazine

Master Investor Magazine 57Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed life sciences specialist ABCAM (LON:ABC) has seen its share price climb by 1.33% to 1,370p (as of 15:15 GMT) as it completed the acquisition of Expedeon’s subsidiaries, which was announced in November.

CEO Alan Hirzel commented: “We are delighted to have completed this transaction and welcome our new colleagues to Abcam. Expedeon’s portfolio of products and technology, combined with Abcam’s antibody and protein strengths, place us well to address the growing need for antibody conjugation and multiplexing solutions“.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *